Firefly Neuroscience News
46 articles
growth-positive
Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America
Firefly Neuroscience, Inc., an AI company focused on improving brain health outcomes, announced a new partnership with HealingMaps and Advanced Behavioral Strategies. This collaboration aims to enhance access to Fireflys FDA-cleared, EEG-based brain health analytics platform for clinics specializing in ketamine, psilocybin, and TMS treatments. The partnership is expected to provide HealingMaps network with preferred pricing and streamlined purchasing options, while offering clinics objective analytics to improve patient care and outcomes. Fireflys platform uses AI to analyze brain activity, providing standardized insights that complement existing treatment models. This partnership is seen as a significant step in expanding Fireflys market reach and supporting sustainable revenue growth.
Partners
growth-positive
Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform
Firefly Neuroscience, Inc. has launched its new CLEAR Platform, a next-generation preprocessing technology designed to enhance EEG data quality. Developed using NVIDIAs L40S GPU, the platform significantly improves processing speed and data fidelity, enabling better detection of neural biomarkers. This advancement is part of Fireflys growth strategy to leverage AI and EEG for transforming neuroscience and clinical development. The CLEAR Platforms release follows Fireflys acceptance into the NVIDIA Connect Program, highlighting a strategic partnership. The platform aims to support pharmaceutical R&D, clinical trials, and patient care by providing cleaner, more reliable EEG data.
Product StagePartners
growth-positive
חברת החלל הפרטית פיירפליי, ששיגרה גשושית שנחתה על הירח, מתכננת לגייס עד 632 מיליון דולר בהנפקה בנאסד"ק לפי שווי של עד 5.6 מיליארד דולר ● לצד חוזים ממשלתיים, שיתופי־פעולה עם נאס”א ו־SpaceX וצבר הזמנות של יותר ממיליארד דולר, החברה סובלת גם מהפסדים כבדים שנמשכים וצפויים להעמיק
Firefly Aerospace, a private space company, plans to raise up to $632 million through an IPO on NASDAQ, valuing the company between $4.9 and $5.6 billion. The company, which successfully landed a spacecraft on the moon, has partnerships with NASA, SpaceX, Northrop Grumman, Lockheed Martin, and L3Harris. Despite its achievements, Firefly has accumulated significant losses, with a net loss of $106 million in 2024 and projected losses continuing. The company has a backlog of over $1.1 billion in orders. AE Industrial Partners is the largest shareholder, holding 41.8% post-IPO.
Public TradingInvestmentPartnersCustomers
growth-positive
Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025
Cognito Therapeutics, a clinical-stage neurotechnology company, has announced promising results from its OVERTURE study on Spectris, an investigational device for treating Alzheimers disease. The study showed that Spectris preserved white matter and myelin integrity, indicating structural neuroprotection. The treatment significantly reduced cognitive and functional decline over 6 and 18 months compared to sham treatment. Spectris is a non-invasive, at-home device that uses synchronized light and sound sensory stimulation to evoke brain gamma oscillations. Collaboration with Firefly Neuroscience aims to identify EEG biomarkers correlating with Spectris clinical response. The findings were presented at the Alzheimer’s Association International Conference 2025, highlighting the devices potential in treating neurodegenerative diseases.
Product StagePartners
growth-positive
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
Firefly Neuroscience, Inc. is collaborating with the Institute of Human Genetics at Heidelberg University Hospital on a study investigating the neurophysiological impact of 15q13.3 CNVs. This collaboration aims to uncover insights into the brains functional architecture in rare genetic conditions. The study uses Fireflys FDA-cleared technology to analyze EEG data from subjects with chromosomal deletions and duplications. The collaboration reflects a shared commitment to advancing precision neuroscience and aims to support future diagnostic and therapeutic strategies for neurodevelopmental disorders. Fireflys AI-powered technology is gaining industry adoption, and the partnership with Prof. Dr. med. Christian Schaaf highlights the value of their technology in advancing brain health outcomes.
Partners
growth-positive
Stran & Company Appoints Veteran Financial Executive Brian M. Posner to its Board of Directors
Stran & Company, Inc., a leader in outsourced marketing solutions, has appointed Brian M. Posner to its Board of Directors as Chairman of the Audit Committee. Posner brings over 40 years of financial leadership experience, having served as CFO for multiple public companies. His appointment is seen as a strategic move to strengthen Strans financial oversight and support its growth strategy. The company specializes in promotional products and loyalty incentives, serving many Fortune 500 companies. Stran aims to build long-term relationships with clients to enhance brand loyalty. The announcement is expected to have a positive impact on the companys growth.
Management Changes
growth-positive
Firefly Neuroscience to be Added to the Russell Microcap® Index
Firefly Neuroscience, Inc., an AI company focused on brain health solutions, announced its inclusion in the Russell Microcap® Index, effective June 30, 2025. This milestone follows its recent Nasdaq listing and reverse merger. The company has made significant strides in 2025, including discovering a cognitive brain age biomarker, joining the NVIDIA Connect program, and expanding its database and IP portfolio through acquiring Evoke Neuroscience. Fireflys FDA-cleared BNA™ Platform is now commercially launched, targeting pharmaceutical companies and medical practitioners. The inclusion in the Russell Index is expected to enhance Fireflys visibility among investors, supporting its growth plans and potential value-creating milestones.
Public TradingAcquisitionFDA approvedPartners
growth-positive
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients
Firefly Neuroscience, Inc. has made significant advancements in Alzheimers research by combining EEG/ERP and volumetric MRI (vMRI) to improve the accuracy of diagnosing subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia. The study highlights that combining these methods increases diagnostic accuracy to 87%. This development builds on Fireflys recent acquisition of Evoke Neuroscience and utilizes their FDA-cleared BNA™ AI platform. The research underscores the potential for earlier detection and intervention in dementia, which can lead to better patient outcomes. The acquisition of Evoke Neuroscience has strengthened Fireflys capabilities, allowing them to leverage a vast database of EEG/ERP records for further research.
AcquisitionFDA approved/pending approval
growth-positive
Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
Firefly Neuroscience, Inc., an AI company focused on improving brain health outcomes, has announced its acquisition of Evoke Neuroscience, Inc., a medical device company. This acquisition significantly expands Fireflys database, intellectual property, and commercial footprint. The transaction involves a payment of $6 million, split equally between cash and Fireflys common stock. Additionally, Evokes investors are eligible for a $500,000 earn-out in Fireflys stock if certain revenue targets are met. This acquisition is a strategic move for Firefly to enhance its proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics technology. The acquisition also marks Fireflys acceptance into the NVIDIA Connect program, furthering its technological and commercial synergies.
AcquisitionPartners
growth-positive
Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
Firefly Neuroscience, Inc., an AI company focused on improving brain health outcomes, has acquired Evoke Neuroscience, Inc., a medical device company. This acquisition is a strategic move to enhance Fireflys proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics technology. The acquisition expands Fireflys assets significantly, including a large proprietary database, patents, and commercial users. The purchase terms include $6 million, split between cash and stock, with a potential $500,000 earn-out. Fireflys partnership with NVIDIA and the acquisition of Evoke are expected to drive rapid growth and innovation in brain health solutions.
AcquisitionPartners
growth-positive
Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
Firefly Neuroscience, Inc., an AI company focused on improving brain health outcomes, has acquired Evoke Neuroscience, Inc., a medical device company. This acquisition is a strategic move to enhance Fireflys proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology. The acquisition includes a $6 million purchase, half in cash and half in Fireflys stock, with an additional $500,000 earn-out contingent on revenue targets. This acquisition significantly expands Fireflys database, patents, and commercial users, and aligns with its partnership with NVIDIA. Fireflys BNA™ technology, developed using AI and machine learning, aids in diagnosing and treating neurological disorders. The acquisition is expected to drive rapid growth and innovation for Firefly.
AcquisitionFDA approvedPartners
growth-positive
Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
Hemostemix Inc., an autologous angiogenic stem cell company, has announced a collaboration with Firefly Neuroscience, Inc., an AI company focused on brain health. The partnership aims to study the effects of Hemostemixs ACP-01 treatment for vascular dementia using Fireflys BNA platform. This Phase 1 clinical trial will involve up to 100 patients, assessing brain wave activity before and after treatment. The collaboration leverages Fireflys extensive EEG database to explore the efficacy of ACP-01. The study aligns with Fireflys partnerships with major companies like Bright Minds, Novartis, and Takeda. Hemostemixs CEO highlights the potential of ACP-01, citing a patients significant improvement ten years post-treatment. Fireflys Executive Chairman emphasizes the transformative potential of their technology in understanding complex brain data.
Product StagePartners
growth-positive
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
Firefly Neuroscience, Inc., an AI company focused on brain health, has extended its cash runway into mid-2026 by receiving $8,824,710 from the exercise of warrants. These funds will support general working capital and the companys strategic initiative to develop a foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology. The BNA™ platform, which utilizes AI and machine learning, provides insights into brain function, aiding in the diagnosis and treatment of neurological and mental disorders. The company is targeting pharmaceutical companies and medical practitioners for commercial use.
PIPE/POFDA approved/pending approval
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
growth-positive
Firefly Neuroscience Accepted into NVIDIA Connect Program
Firefly Neuroscience, Inc., an AI company focused on brain health, has been accepted into the NVIDIA Connect program. This collaboration will provide Firefly with advanced software development resources and technical training to support its strategic initiative of building the worlds first foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology. The partnership is expected to enhance Fireflys capabilities in developing innovative solutions for neurological and mental disorders. The company is launching its BNA™ technology commercially, targeting pharmaceutical companies and medical practitioners. This development marks a significant milestone for Firefly, positioning it for growth and expansion in the medtech industry.
PartnersProduct Stage
growth-positive
Firefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics
Firefly Neuroscience, Inc., an AI company focused on improving brain health outcomes, is celebrating the recognition of Dr. Christopher Wilson by the University of Waterloo’s Faculty of Engineering for his contributions to research. Dr. Wilson, a key member of Firefly’s Advisory Development Board, has been instrumental in a new brain model initiative. Fireflys Brain Network Analytics (BNA™) technology, which has received FDA clearance, is now being launched commercially. This technology aims to revolutionize diagnostic and treatment monitoring for neurological and mental disorders. The company is targeting pharmaceutical companies and medical practitioners for clinical use. Dr. Wilsons work in quantum computing and his collaborations have secured significant research funding, further enhancing Fireflys growth prospects.
Product StageCustomers
growth-positive
Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care
Firefly Neuroscience, Inc., an AI company focused on brain health, has highlighted two studies demonstrating the effectiveness of its FDA-cleared BNA™ platform. The platform provides objective measures of drug efficacy and cognitive change, crucial for neuropharmacology and psychiatry. The first study, conducted with Novartis, showed the potential of EEG as a biomarker in drug development, particularly for the antidepressant MIJ821. The second study demonstrated the use of EEG in assessing cognitive changes in MDD patients, underscoring the platforms role in personalized psychiatry. These studies reinforce Fireflys innovative approach to improving neurological and mental health outcomes.
Product StagePartners
growth-positive
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform
Firefly Neuroscience, Inc., an AI company, has announced advancements in its research to assess brain age using its FDA-cleared BNA™ technology platform. This innovative approach utilizes EEG data to estimate the biological age of a persons brain, potentially aiding in early screening for Alzheimers. The company is launching BNA™ commercially, targeting pharmaceutical companies and medical practitioners. Fireflys technology has the potential to revolutionize diagnostic and treatment monitoring methods for various neurological and mental disorders. The announcement highlights Fireflys commitment to innovation in brain health, aiming to make a significant impact on patients lives.
Product StageFDA approved/pending approval
growth-positive
Firefly Neuroscience Closes on Financing of up to $12.4 Million
Firefly Neuroscience, Inc., an AI company focused on improving brain health outcomes, announced the closing of a $12.4 million financing deal. This includes $2.4 million in senior secured convertible notes and an equity line of credit for up to $10 million. The funds will be used for growth and commercialization of its FDA-510(k) cleared Brain Network Analytics (BNA™) technology. The technology, developed using AI and machine learning, aids in diagnosing and treating neurological and mental disorders. Firefly plans to partner with neuroscience pharmaceutical companies and support US neurologists and psychiatrists. The financing strengthens Fireflys balance sheet, allowing it to accelerate commercialization pathways and improve patient outcomes.
InvestmentCustomersPartners
growth-positive
Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman
Firefly Neuroscience, Inc., an AI company focused on brain health, has appointed Greg Lipschitz as Executive Chairman, effective December 3, 2024. This management change comes as the company prepares to commercialize its FDA-cleared Brain Network Analytics (BNA™) technology, which aids in diagnosing and monitoring neurological and mental disorders. The transition is seen as a strategic move to leverage Lipschitzs extensive capital markets experience. The outgoing Executive Chairman, David Johnson, resigned amicably. Fireflys BNA™ technology is now being launched commercially, targeting pharmaceutical companies and medical practitioners. The company is well-positioned at the intersection of AI and brain health, aiming to improve patient outcomes.
Management Changes
growth-negative
Firefly Neuroscience Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$0.18 loss in 3Q 2023)
Firefly Neuroscience reported a net loss of US$4.29 million, which is a significant increase from the previous quarters loss of US$3.64 million. The loss per share also deteriorated to US$0.61 from US$0.18. The companys shares have decreased by 2.2% over the past week. The article highlights that Firefly Neuroscience has five warning signs, four of which are concerning. The analysis provided is based on historical data and analyst forecasts, and it is not intended as financial advice. Simply Wall St, the source of the article, does not hold any position in the stocks mentioned.
growth-positive
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
Firefly Neuroscience, Inc., an AI company focused on brain health, successfully listed on Nasdaq under the symbol AIFF. The company has formed strategic partnerships with neuroscience pharmaceutical companies like Bright Minds Bioscience, Novartis, and Takeda to enhance drug development and patient care. Fireflys FDA-cleared Brain Network Analytics (BNA™) technology is being used in various clinical trials and collaborations. The company aims to improve outcomes for neurological and mental disorders by leveraging its extensive EEG database. Recent operational highlights include a merger with WaveDancer Inc., partnerships with Zeto, Inc., and the appointment of Dr. Stella Vnook to the Board of Directors.
PartnersPublic TradingManagement Changes
growth-positive
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
Firefly Neuroscience, Inc., an AI company focused on improving brain health outcomes, announced its participation in the Capital Event Management Conference in Miami. The company has developed Brain Network Analytics (BNA™), a technology that has received FDA 510(k) clearance and is now being launched commercially. BNA™ uses AI and machine learning to analyze EEG data, aiding in the diagnosis and treatment of neurological and mental disorders. The conference participation is aimed at building relationships with investors and promoting their innovative solutions. Fireflys technology targets pharmaceutical companies and medical practitioners, offering insights into brain function to optimize patient outcomes.
Product StageFDA approved/pending approval
growth-positive
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Firefly Neuroscience, Inc., an AI company focused on brain health solutions, announced the granting of 557,885 restricted shares to David Johnson, the new Executive Chairman, as part of an employment agreement. The company has developed Brain Network Analytics (BNA™), a technology cleared by the FDA, which aids in diagnosing and monitoring neurological and mental disorders. BNA™ is now being launched commercially, targeting pharmaceutical companies and medical practitioners. The technology uses AI and machine learning on a proprietary database of EEGs to provide insights into brain function. The article highlights the companys growth trajectory, FDA clearance, and recent management changes.
Management ChangesFDA approved/pending approval
growth-positive
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
Bright Minds Biosciences is collaborating with Firefly Neuroscience to analyze EEG data in its Phase 2 clinical trial, BREAKTHROUGH, for BMB-101, a 5-HT2C receptor agonist. The study targets Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE) in adults. This collaboration follows a successful Phase 1 study using Fireflys FDA-cleared AI technology. BMB-101 aims to address drug resistance in epilepsy, with potential broad applicability across epilepsy patients. The partnership with Firefly highlights the use of advanced AI technology to enhance clinical trial outcomes and underscores Bright Minds commitment to innovative neurological disorder treatments.
Product StagePartners
growth-positive
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
Firefly Neuroscience, Inc., an AI company focused on brain health, collaborated with Bright Minds Biosciences to analyze data from a Phase 1 study of Bright Minds lead compound, BMB-101. The study showed positive results using Fireflys advanced AI BNA technology platform. The collaboration involved using FDA-approved EEG headsets provided by Fireflys partner, Zeto. The studys success validates the approach and sets the stage for BMB-101 to move to Phase 2. Fireflys CEO, Jon Olsen, expressed satisfaction with the collaboration and looks forward to future partnerships. This collaboration highlights Fireflys role in advancing clinical studies through AI technology.
Product StagePartners
growth-positive
Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder
Firefly Neuroscience, Inc., an AI company focused on brain health, announced that its FDA-510(k) cleared Brain Network Analytics (BNA™) platform will be used in Arrivo Bioventures Phase 1 study of SP-624, a SIRT6 activator. The study aims to identify biomarkers and assess the impact of SP-624 on neurological pathways in patients with major depressive disorder (MDD). The collaboration underscores a commitment to advancing treatments for MDD, particularly in women. Previous studies showed significant efficacy in female subjects. The study will explore SP-624s activity and potential biomarkers for future research in neurological conditions.
Product StagePartners
growth-positive
Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
Firefly Neuroscience, Inc., an AI company, announced advancements in its Brain Network Analytics (BNA™) technology, following successful collaborations with Takeda and Novartis. These partnerships highlight the value of Fireflys AI-based technology in neuroscience drug development, offering objective measures of brain activity to enhance trial design and accelerate drug approval processes. Fireflys BNA™ technology, which has received FDA 510(k) clearance, is now being launched commercially. It aims to reduce costs and improve clinical outcomes by precisely measuring drug effects and identifying responsive patients. The company plans to expand its partnerships with pharmaceutical companies, leveraging its comprehensive database of brain wave tests.
PartnersFDA approved/pending approvalProduct Stage
growth-positive
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
Firefly Neuroscience, Inc. has announced a strategic partnership with Zeto, Inc. to expand the reach of its FDA-cleared Brain Network Analytics (BNA™) technology. This collaboration will allow Firefly to distribute Zetos FDA-cleared EEG headset devices and cloud platform, enhancing accessibility to healthcare providers. The integration of Fireflys BNA™ technology with Zetos EEG platform aims to provide deeper insights into neurological conditions, improving patient outcomes. Zetos devices are already in use in over 200 hospitals and neurology offices, and this partnership is expected to further expand their user base. The collaboration represents a significant step forward in addressing brain health needs.
Partners
growth-positive
Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors
Firefly Neuroscience, Inc., an AI company focused on improving brain health outcomes, announced the appointment of Stella Vnook, Ph.D., to its Board of Directors as of August 19, 2024. Dr. Vnook, with over 25 years of experience in biotechnology and life sciences, will serve as Chairperson of the Nominating Committee. Her extensive background includes roles as CEO of Likarda Biotech and Founder of OralBiolife Biosciences. Fireflys Brain Network Analytics (BNA™) technology, which has FDA-510(k) clearance, is being launched commercially to aid pharmaceutical companies and medical practitioners. The appointment is expected to drive strategic growth and innovation for Firefly.
Management Changes
growth-positive
Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11
Firefly Neuroscience, Inc., an AI company focused on improving brain health outcomes, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company recently closed a merger with WaveDancer and has received FDA 510(k) clearance for its Brain Network Analytics (BNA™) platform. This platform, developed using AI and machine learning, aids in diagnosing and optimizing treatment for neurological and mental disorders. Firefly is launching BNA™ commercially, targeting pharmaceutical companies and medical practitioners. The company aims to provide clinicians with comprehensive insights into brain function, enhancing diagnosis and treatment of conditions like depression, dementia, and ADHD.
Acquired-byFDA approved/pending approvalPublic Trading
growth-positive
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
Firefly Neuroscience, Inc., an AI technology company, announced a shareholder update call scheduled for September 4, 2024. The company has developed the Brain Network Analytics (BNA) platform, which has received FDA 510(k) clearance. This platform uses AI and machine learning to provide insights into brain function, aiding in the diagnosis and treatment of mental illnesses and neurological disorders. Firefly has invested around $60 million over 15 years in developing this platform, which is now being launched commercially. The BNA platform targets pharmaceutical companies and medical practitioners, offering a comprehensive database of brain wave tests to enhance patient outcomes.
Product StageFDA approvedCustomers
Growth-Positive
WaveDancer and Firefly Neuroscience, an AI-Driven Brain Health Company, Each Receive Respective Stockholder Approvals for Merger
WaveDancer, Inc. and Firefly Neuroscience, Inc., an AI-driven brain health company, have received the necessary stockholder approvals to proceed with their merger. The merger will see WaveDancer reinvent itself as an AI-enabled neurological health platform, focusing on the continued development and commercialization of Firefly’s FDA-approved Brain Network Analytics software platform. The deal is expected to close in Q2 2024, with the combined company operating under the name Firefly Neuroscience, Inc. and trading on the Nasdaq Capital Market.
Acquired-by
growth-positive
SEC Declares Form S-4 Registration Statement Effective for Proposed Merger of WaveDancer, Inc. and Firefly Neuroscience, Inc.
WaveDancer, Inc. and Firefly Neuroscience, Inc. have announced that their proposed merger has been declared effective by the Securities and Exchange Commission. The merger is expected to close earlier in the second quarter of 2024 than originally anticipated. The merger will bring Fireflys FDA-cleared, Brain Network Analytics (BNA™) platform, developed with artificial intelligence (AI), to the Nasdaq. The BNA™ Platform will be introduced to clinics and pharmaceutical companies around the world. The combined companys common stock is anticipated to be listed on NASDAQ under the ticker symbol AIFF.
AcquisitionPublic Trading
Growth-Positive
WaveDancer Announces Merger Agreement with Firefly Neuroscience
WaveDancer, Inc. has announced a definitive merger agreement with Firefly Neuroscience, Inc. The merger will combine the companies in an all-stock transaction, with the combined company focusing on the development and commercialization of Firefly’s Artificial Intelligence driven Brain Network Analytics (BNA™) platform. The platform has previously been cleared by the U.S. Food and Drug Administration. The merger is expected to close in Q1-2024, with the combined company operating under the name Firefly Neuroscience, Inc. and trading on the Nasdaq Capital Market.
Acquired-byManagement Changes
growth-positive
Firefly Neuroscience Inc. Unveils Groundbreaking Insights on BNA™ as an Effective Disease Management Program in Psychiatric Practice
Firefly Neuroscience Inc. has announced the findings of a study that explored the benefits of its AI-powered EEG analysis platform, Brain Network Analytics (BNA™), in psychiatric practice. The study collected data from 2,253 patients at a US psychiatric clinic and focused on patients with Major Depressive Disorder, Generalized Anxiety Disorder, and Attention-Deficit/Hyperactivity Disorder. The results showed that BNA™-guided therapy led to increased treatment adherence, reduced need for medication switching, and improved overall patient well-being. The company aims to improve patient outcomes and contribute to the betterment of mental health and cognitive disorders globally.
Customers
growth-positive
STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD
STALICLA and Firefly Neuroscience have entered into a partnership agreement to develop electroencephalogram (EEG) as a biomarker for subgroups of patients with Autism Spectrum Disorder (ASD). The partnership will leverage their technological platforms to advance EEG validation in upcoming Phase 2 clinical trials. The goal is to establish and expand EEG as a biomarker in the field of ASD, reinforcing the stratification capacity and prediction of treatment response. STALICLAs lead asset, STP1, has shown positive target engagement through EEG signal modulation in brain areas of interest. The partnership aims to advance precision medicine for neurodevelopmental disorders and improve treatment for people with ASD.
Partners
growth-positive
elminda and RI.Group to Form RI.Mind - a Joint Venture to Apply elminda's Brain Analytics Technology for Personalization of Medical Cannabis
elminda Ltd. has partnered with RI.Group Investment Management Ltd. to address the challenge of personalizing medical cannabis health. The partnership aims to change the way cannabis is consumed by providing tools and data to predict, identify, prescribe, and optimize the most appropriate medical cannabis drug for each patient. The legal cannabis market is expected to reach $75 billion by 2030, and elminda and RI.Mind aim to make personalized healthcare accessible and effective in the cannabis space. elmindas brain analytics product, the BNA™, helps physicians select the most effective treatment and monitor its effect in the brain for patients with brain-related disorders. The partnership between elminda and RI.Group is seen as a critical step in the cannabis supply chain.
PartnersInvestment
growth-positive
The Villages Health and elminda joint Study Receives Erickson Foundation Award for Excellence in Aging Research at 2018 APHA Annual Meeting
elminda Ltd., a medical technology company, has received the Erickson Foundation Award for Excellence in Aging Research for its study on the utility of its Brain Network Analytics (BNA) platform in assessing cognitive function in older adults. The study showed the potential of BNA in early detection of brain disorders and distinguishing between healthy aging brains and those experiencing adverse outcomes. The collaboration between elminda and The Villages Health was recognized for its real-world utility. The BNA platform has the potential to become a go-to analysis tool for diagnosing and detecting brain functional problems. The award will be presented at the American Public Health Association annual meeting in November 2018.
Partners
growth-positive
elminda BNA technology unlocking secrets of brain disorders - BioTuesdays
elmindas Brain Networks Analytics (BNA) technology combines Big Data and AI-driven analytics to measure and analyze brain function. The company aims to provide early detection of brain disorders and improve therapeutic interventions. elminda has a large database of brain recordings and is seeking FDA approval to expand the use of BNA. The companys business model is based on charging per test and is expected to generate $1 million in revenue in 2018. elminda has partnered with Novartis for the development of new brain therapeutics and has conducted pilot programs in China and the US. The company is exploring financing options and potential public listing on a US exchange.
CustomersPartners
growth-positive
Exit near? Israeli brain-tech firm ElMindA raises nearly $30m
Israeli biotechnology firm ElMindA has raised $28 million in a Series C financing round. The funding will be used to enhance ElMindAs proprietary Brain Network Activation system and prepare it for commercial and clinical adoption. ElMindAs system uses a sensor-laden helmet to measure brain activity without the need for invasive sensors. The data is analyzed using patented algorithms to create three-dimensional images of brain network activation patterns. The system can detect early stages of degenerative brain diseases and assist in treatment planning for brain disorders. The investors in the funding round include Shanda Group, Wexford Capital, WR Hambrecht & Co, Palisade Capital Management, OurCrowd, Kraft Group, and Healthcrest AG.
Investment
growth-positive
Israeli neuroscience co ElmindA raises $28m
Israeli startup ElMindA Ltd. has completed a $28 million Series C financing round to further develop its Brain Network Activation system for neurological disorders. The investors include Shanda Group, The Kraft Group, Wexford Capital, WR Hambrecht & Co, Palisade Capital Management, OurCrowd, and Healthcrest AG. ElMindA was founded in 2006 and has raised a total of $43 million to date. The funds will be used for the advancement of ElMindAs proprietary BNA system, as well as for commercial and clinical adoption. BNA is a non-invasive technology for measuring and analyzing brain function, with the potential to impact an estimated two billion people worldwide living with neurological and psychiatric disorders. ElMindAs CEO, Ronen Gadot, expressed excitement about the support from the investors and the potential of BNA technology to positively impact peoples lives.
Investment
ElMindA and Consumer Physics Named to World Economic Forum's Most Promising Top 49 Tech Companies Worldwide
growth-positive
OurCrowd invests in Israeli 'helmet' to diagnose Parkinson's
Israeli crowdfunding platform OurCrowd announced its 67th investment in ElMindA, a company that has developed the worlds first FDA-approved neural functional assessment tool. This investment marks a milestone for OurCrowd, which has invested over $110 million from its accredited investor base in various sectors. OurCrowd identifies early-stage investment opportunities and allows its members to choose which deals to participate in. The platform co-invests in all deals and manages ongoing investments. OurCrowd focuses on tech that can make a difference in peoples lives. ElMindAs technology has the potential to mitigate sports injuries and advance brain research. The companys BNA system can detect degenerative brain diseases and assist in treatment planning for brain disorders. OurCrowd aims to drive the transformation of Israels start-up ecosystem into a scale-up nation.
Investment
growth-positive
ElMindA receives FDA approval for brain-scanner
Israeli company ElMindA has received FDA approval to market its BNA Analysis system for mapping brain activity. The product will be marketed for diagnosing head injuries in emergency rooms and sports medicine. ElMindA has signed deals with parties in the medical market and has a deal with a leading sports medicine service provider in the US. The BNA Analysis system uses electrodes placed on the scalp to non-invasively read brain activity. ElMindA was established in 2006 and has raised $15 million since its founding.
CustomersPartners
growth-positive
ElMindA, Purdue Pharma to collaborate on brain imaging
ElMindA Ltd., a company specializing in neural network mapping technology, has entered a strategic, multi-year research collaboration with Purdue Pharma LP. This partnership aims to use ElMindAs brain imaging system to gather data on brain function changes during clinical trials for new pain medications. The collaboration is expected to generate several million dollars in revenue for ElMindA. The company, founded in 2006, has raised $15 million in total, with $10 million raised last year. Notable investors include Sammy Sagol and Robert Kraft. ElMindAs technology is distinct in its ability to map neural networks across different brain regions, offering insights into neurological, psychiatric, and pain-related disorders.
PartnersInvestment
